[1] [1] HAN Z G. Functional genomic studies: insights into the pathogenesis of liver cancer［J］. Annual Review of Genomics and Human Genetics, 2012, 13: 171-205.

[2] [2] KULIK L, EL-SERAG H B. Epidemiology and management of hepatocellular carcinoma［J］. Gastroenterology, 2019, 156(2): 477-491.

[3] [3] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA: A Cancer Journal for Clinicians, 2021, 71(3): 209-249.

[4] [4] CUCARULL B, TUTUSAUS A, RIDER P, et al. Hepatocellular carcinoma: molecular pathogenesis and therapeutic advances［J］. Cancers, 2022, 14(3): 621.

[5] [5] EASWARAN H, TSAI H C, BAYLIN S B. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance［J］. Molecular Cell, 2014, 54(5): 716-727.

[6] [6] VISVADER J E, LINDEMAN G J. Cancer stem cells: current status and evolving complexities［J］. Cell Stem Cell, 2012, 10(6): 717-728.

[7] [7] PINYOL R, MONTAL R, BASSAGANYAS L, et al. Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 storm trial［J］. Gut, 2019, 68(6): 1065-1075.

[8] [8] WANG H V, VAUPEL K, BUETTNER R, et al. Identification and embryonic expression of a new AP‐2 transcription factor, AP‐2ε［J］. Developmental Dynamics: An Official Publication of the American Association of Anatomists, 2004, 231(1): 128-135.

[9] [9] ZHAO F, SATDA M, LICHT J D, et al. Cloning and characterization of a novel mouse AP-2 transcription factor, AP-2δ, with unique DNA binding and transactivation properties［J］. Journal of Biological Chemistry, 2001, 276(44): 40755-40760.

[10] [10] ECKERT D, BUHL S, WEBER S, et al. The AP-2 family of transcription factors［J］. Genome Biology, 2005, 6(13): 1-8.

[11] [11] KANNAN P, TAINSKY M A. Coactivator PC4 mediates AP-2 transcriptional activity and suppresses ras-induced transformation dependent on AP-2 transcriptional interference［J］. Molecular and Cellular Biology, 1999, 19(1): 899-908.

[12] [12] LI Q, DASHWOOD R H . Activator protein 2alpha associates with adenomatous polyposis coli/beta-catenin and inhibits beta-catenin/T-cell factor transcriptional activity in colorectal cancer cells［J］. Journal of Biological Chemistry, 2004, 279(44): 45669-45675.

[13] [13] STABACH P R, THIYAGARAJAN M M, WOODFIELD G W, et al. AP2α alters the transcriptional activity and stability of p53［J］. Oncogene, 2006, 25(15): 2148-2159.

[14] [14] WAJAPEYEE N, BRITTO R, RAVISHANKAR H M, et al. Apoptosis induction by activator protein 2α involves transcriptional repression of Bcl-2［J］. Journal of Biological Chemistry, 2006, 281(24): 16207-16219.

[15] [15] ORSO F, JAGER R, CALOGERO R A, et al. AP-2α regulates migration of GN-11 neurons via a specific genetic programme involving the Axl receptor tyrosine kinase［J］. BMC Biology, 2009, 7(1): 1-18.

[16] [16] ORSO F, PENNA E, CIMINO D, et al. AP-2alpha and AP-2gamma regulate tumor progression via specific genetic programs.［J］. The FASEB Journal, 2008(8): 22.

[17] [17] PARK M J, KWAK H J, LEE H C, et al. Nerve growth factor induces endothelial cell invasion and cord formation by promoting matrix metalloproteinase-2 expression through the phosphatidylinositol 3-kinase/Akt signaling pathway and AP-2 transcription factor［J］. Journal of Biological Chemistry, 2007, 282(42): 30485-30496.

[18] [18] HUANG W, CHEN C, LIANG Z, et al. AP-2α inhibits hepatocellular carcinoma cell growth and migration［J］. International Journal of Oncology, 2016, 48(3): 1125-1134.

[19] [19] ZHANG W, WU Y, HOU B, et al. A SOX9‐AS1/miR‐5590‐3p/SOX9 positive feedback loop drives tumor growth and metastasis in hepatocellular carcinoma through the Wnt/β‐catenin pathway［J］. Molecular Oncology, 2019, 13(10): 2194-2210.

[20] [20] KLUM S, ZAOUTER C, ALEKSEENKO Z, et al. Sequentially acting SOX proteins orchestrate astrocyte‐ and oligodendrocyte‐specific gene expression［J］. EMBO Reports, 2018, 19(11): e46635.

[21] [21] SURYO RAHMANTO A, SAVOV V, BRUNNER A, et al. FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma［J］. The EMBO Journal, 2016, 35(20): 2192-2212.

[22] [22] ALEMAN A, ADRIEN L, LOPEZ-SERRA L, et al. Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays［J］. British Journal of Cancer, 2008, 98(2): 466-473.

[23] [23] PASSERON T, VALENCIA J C, NAMIKI T, et al. Upregulation of SOX9 inhibits the growth of human and mouse melanomas and restores their sensitivity to retinoic acid［J］. The Journal of Clinical Investigation, 2009, 119(4): 954-963.

[24] [24] WANG H, LIAN P, ZHENG P S. SOX9, a potential tumor suppressor in cervical cancer, transactivates p21WAF1/CIP1 and suppresses cervical tumor growth［J］. Oncotarget, 2015, 6(24): 20711.

[25] [25] CHAKRAVARTY G, MOROZ K, MAKRIDAKIS N M, et al. Prognostic significance of cytoplasmic SOX9 in invasive ductal carcinoma and metastatic breast cancer［J］. Experimental Biology and Medicine, 2011, 236(2): 145-155.

[26] [26] SANTOS J C, CARRASCO-GARCIA E, GARCIA-PUGA M, et al. SOX9 elevation acts with canonical WNT signaling to drive gastric cancer progression SOX9 and gastric cancer［J］. Cancer Research, 2016, 76(22): 6735-6746.

[27] [27] WANG L, HE S, YUAN J, et al. Oncogenic role of SOX9 expression in human malignant glioma［J］. Medical Oncology, 2012, 29(5): 3484-3490.

[28] [28] PREVOSTEL C, RAMMAH-BOUAZZA C, TRAUCHESSEC H, et al. SOX9 is an atypical intestinal tumor suppressor controlling the oncogenic Wnt/ss-catenin signaling［J］. Oncotarget, 2016, 7(50): 82228.

[29] [29] GRIMM D, BAUER J, WISE P, et al. The role of SOX family members in solid tumours and metastasis［J］. Seminars in Cancer Biology, 2020, 67: 122-153.

[30] [30] CHEN Y, QIAN B, SUN X, et al. Sox9/INHBB axis-mediated crosstalk between the hepatoma and hepatic stellate cells promotes the metastasis of hepatocellular carcinoma［J］. Cancer Letters, 2021, 499: 243-254.

[31] [31] LIU C, REN Y F, DONG J, et al. Activation of SRY accounts for male-specific hepatocarcinogenesis: implication in gender disparity of hepatocellular carcinoma［J］. Cancer Letters, 2017, 410: 20-31.

[32] [32] RICHTIG G, AIGELSREITER A, SCHWARZENBACHER D, et al. SOX9 is a proliferation and stem cell factor in hepatocellular carcinoma and possess widespread prognostic significance in different cancer types［J］. PLoS One, 2017, 12(11): e0187814.

[33] [33] POPP F C, POPP M C, ZHAO Y, et al. Protocol of the PANCALYZE trial: a multicenter, prospective study investigating the tumor biomarkers CXCR4, SMAD4, SOX9 and IFIT3 in patients with resected pancreatic adenocarcinoma to predict the pattern of recurrence of the disease［J］. BMC Cancer, 2017, 17(1): 1-9.

[34] [34] GUO X, XIONG L, SUN T, et al. Expression features of SOX9 associate with tumor progression and poor prognosis of hepatocellular carcinoma［J］. Diagnostic Pathology, 2012, 7(1): 1-7.